Maternal and Neonatal Outcomes Associated with Treating Hypertension in Pregnancy at Different Thresholds
ConclusionsInitiation of antihypertensive medication at mild-to-moderate BP thresholds (140-155/90-105  mm Hg; with the largest risk consistently associated with treatment at 140/90 mm Hg) may be associated with adverse maternal and neonatal outcomes. Limitations include inability to measure medication adherence. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 14, 2023 Category: Drugs & Pharmacology Authors: Lyndsay A. Avalos, Romain S. Neugebauer, Nerissa Nance, Sylvia E. Badon, T. Craig Cheetham, Thomas R. Easterling, Kristi Reynolds, Abisola Idu, Zoe Bider ‐Canfield, Victoria L. Holt, Sascha Dublin Tags: RESEARCH ARTICLE Source Type: research

Novel and replicated clinical and genetic risk factors for toxicity from high ‐dose methotrexate in pediatric acute lymphoblastic leukemia
AbstractMethotrexate (MTX) is a key component of treatment for high-risk pediatric acute lymphoblastic leukemia (ALL) but may cause acute kidney injury and prolonged hospitalization due to delayed clearance. We conducted a retrospective cohort study of pediatric patients with ALL who received 4000-5000 mg/m2 of MTX to identify clinical and genetic factors that may predict which children are at risk for creatinine increase and prolonged MTX clearance. We performed germline genotyping to determine genetic ancestry and allele status for 49 single nucleotide polymorphisms (SNPs) identified from the literature as related to MTX...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 11, 2023 Category: Drugs & Pharmacology Authors: Mark Zobeck, M. Brooke Bernhardt, Kala Y. Kamdar, Karen R. Rabin, Philip J. Lupo, Michael E. Scheurer Tags: RESEARCH ARTICLE Source Type: research

Correlation between Partial Thromboplastin Time and Thromboelastography in Adult Critically Ill Patients Requiring Bivalirudin for Extracorporeal Membrane Oxygenation
ConclusionsModerate correlation was found between TEG R time and aPTT associated with bivalirudin during ECMO in critically ill adults. Further research is warranted to address the optimal test to guide clinical decision-making for anticoagulation dosing in ECMO patients. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 10, 2023 Category: Drugs & Pharmacology Authors: Mitchell S. Buckley, Grace E. Benanti, Jordan Meckel, Luwam A. Tekle, Brian Gilbert, Daniel Puebla Neira, Dakota A. McNierney, Grace Korkames, Melanie Yerondopoulos, Andrew Park, Jennifer A. O ’Hea, Robert MacLaren Tags: RESEARCH ARTICLE Source Type: research